The Federal Trade Commission announced Friday it has cleared the latest pharmaceutical merger proposal as a string of deals in the industry sweeps across the globe.
Forest Laborites has been cleared to acquire Furiex Pharmaceuticals, a deal made for $1.46 billion, according to reports. Forest first announced in late April that it plans to acquire the company for its gastrointestinal treatment portfolio.
The merger is one of many in the works for the pharmaceutical market, though not all are sure to consummate. Recently, Pfizer failed to acquire AstraZeneca despite several bids that ultimately reached a $119 billion offer. Additionally, Valeant is currently looking to acquire the maker of Botox, Allergan, and has also recently increased its offer.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.